Skip to main content
What types of page to search?

Alternatively use our A-Z index.

Publications

What type of publication do you want to show?

2023

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

Taieb, J., Seufferlein, T., Reni, M., Palmer, D. H., Bridgewater, J. A., Cubillo, A., . . . Macarulla, T. (2023). Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe. BMC CANCER, 23(1). doi:10.1186/s12885-023-11377-1

DOI
10.1186/s12885-023-11377-1
Journal article

PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research

Jones, R. P., Mielgo, A., Schmid, M., Bury, D., Andrews, T., Burdak-Rothkamm, S., . . . Vimalachandran, D. (2023). PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research. BRITISH JOURNAL OF SURGERY. doi:10.1093/bjs/znad097

DOI
10.1093/bjs/znad097
Journal article

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma

de Andres, M. P., Jackson, R. J., Felipe, I., Zagorac, S., Pilarsky, C., Schlitter, A. M., . . . Real, F. X. (2023). GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. GUT, 72(3), 535-548. doi:10.1136/gutjnl-2021-325803

DOI
10.1136/gutjnl-2021-325803
Journal article

2022

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.

Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., . . . European Study Group for Pancreatic Cancer. (2022). Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.. The lancet. Gastroenterology & hepatology, S2468-1253(22)00348-X. doi:10.1016/s2468-1253(22)00348-x

DOI
10.1016/s2468-1253(22)00348-x
Journal article
  1. 1
  2. 2
  3. 3
  4. ...
  5. 23